Norges Bank Prelude Therapeutics Inc Transaction History

Norges Bank

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 09, 2022	SELL	$6.9 - $13.22 $172,500 - $330,500	-25,000 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$11.89 - $31.74 $297,250 - $793,500	25,000 New	25,000 $311,000
Q3 2021 Nov 14, 2022	BUY	$25.78 - $38.65 $5.73 Million - $8.6 Million	222,400 New	222,400 $6.95 Million
Q3 2021 Nov 05, 2021	SELL	$25.78 - $38.65 $644,500 - $966,250	-25,000 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$28.63 - $44.3 $715,750 - $1.11 Million	25,000 New	25,000 $716,000
Q2 2021 Aug 10, 2021	SELL	$28.63 - $44.3 $715,750 - $1.11 Million	-25,000 Closed	0 $0
Q1 2021 May 09, 2022	BUY	$39.27 - $91.68 $981,750 - $2.29 Million	25,000 New	25,000 $1.08 Million
Q1 2021 May 07, 2021	SELL	$39.27 - $91.68 $785,400 - $1.83 Million	-20,000 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$28.81 - $88.94 $576,200 - $1.78 Million	20,000 New	20,000 $1.43 Million
Q4 2020 Feb 10, 2021	SELL	$28.81 - $88.94 $576,200 - $1.78 Million	-20,000 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$26.2 - $30.13 $524,000 - $602,600	20,000 New	20,000 $603,000

35.7M

500

300

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $47.3M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.